Amniox Medical Announces Initiation Of Prospective, Randomized, Controlled Clinical Study Of Chronic Wounds

ATLANTA--(BUSINESS WIRE)--Amniox Medical, Inc., a developer and marketer of restorative therapies processed from amniotic membrane and umbilical cord, announces the initiation of a randomized, controlled clinical trial of its proprietary product in patients with chronic wounds. The multi-center, randomized, parallel, crossover design study of non-healing diabetic foot ulcers compares Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) versus standard of care. The study is designed to demonstrate the Company’s technology is a clinically effective and cost efficient option for patients.

Help employers find you! Check out all the jobs and post your resume.